MedPath

Comparative evaluation of triple therapy with high dose amoxicillin versus bismuth-based therapy in second-line therapy for eradication of helicobacter pylori infection in childre

Phase 3
Recruiting
Conditions
H.pylori Gastritis.
B98.0
Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Registration Number
IRCT20191022045195N1
Lead Sponsor
Qazvin University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Children with Helicobacter pylori infection who are known to be resistant to the first stage of eradication

Exclusion Criteria

Patients who have had a positive history of taking drugs such as antibiotics during the last 4 weeks,  Bismuth, proton pump inhibitor, histamine receptor antagonist 2 or non-steroidal anti-inflammatory drug are excluded

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The percentage of patients with Helicobacter pylori antigen in the stool sample is negative. Timepoint: Helicobacter pylori antigen assay is performed within 4 to 6 weeks after completion of treatment. Method of measurement: Helicobacter pylori antigen in stool sample by ELISA.
Secondary Outcome Measures
NameTimeMethod
Percentage of people with side effects while taking the drug. Timepoint: From the beginning of the drug to the end of the study. Method of measurement: Self-expression of the patient, parents or carers.;Percentage of patients who were fully compliant with medication. Timepoint: Up to 4 weeks after starting the drug. Method of measurement: Self-expression of the patient, parents or carers.
© Copyright 2025. All Rights Reserved by MedPath